Gradientech stock
Gradientech is a Swedish in vitro diagnostics company specializing in ultra-fast antibiotic susceptibility testing (AST). Their flagship product, QuickMIC®, is designed to empower modern microbiology laboratories by delivering accurate minimum inhibitory concentration (MIC) values directly from positive blood cultures within 2-4 hours. The technology enables faster and more informed treatment decisions, improving healthcare and reducing the spread of antibiotic resistance.
Gradientech share price
Current bids and asks, the latest trade and Gradientech's valuation. The full price history opens once you create an account.
Account required
See the full price history
Complete transaction history, order depth and valuation data are free once you open an account.
Create accountOther companies you may be interested in
Note: Share price is from each company's latest known share issue. The change compares it with the previous issue and does not account for splits or differing share classes.
Gradientech new issues and valuations
| Date | Type | Share price | Valuation The company's valuation after the funding round was completed (Post-money). | Amount The specific amount raised in this funding round. |
|---|---|---|---|---|
| Q2 2025 | Share issuance | 17.5 SEK | SEK 565,800,000 | Locked |
| Q1 2025 | Share issuance | 17.5 SEK | SEK 536,900,000 | Locked |
| Q4 2024 | Share issuance | 17.5 SEK | SEK 505,200,000 | Locked |
See the amount raised in every funding round
Free · about two minutes
Note: Information on Gradientech's funding rounds, amounts, and valuation is sourced from news media and public sources unless otherwise stated. Information on capital structure is sourced from public company registers unless otherwise stated.
Buy or sell Gradientech shares
Place a bid or a sell order. Accumeo matches you with the counterparty and handles the transfer through an established process.
Create accountFree · about two minutes
Unsure about the price picture in Gradientech, or sitting on a larger holding? Book fifteen minutes with the desk before you place an order.
Book a callReply within one business day
Have any questions about buying or selling shares in private companies? Don't hesitate to contact us.
How trading works
From account to completed transfer
1. Create an account
Identification is handled with BankID. The account is free and carries no obligation to trade.
2. Study the company
Price history, completed trades, ownership and documents gathered in one place.
3. Place your order
State the number of shares, the price and any conditions. Your order is anonymous to the market.
4. We handle settlement
On a match we draw up a share transfer agreement covering price, share count and closing date.
Settlement follows an established process with third-party verification of payment and share transfer, minimizing counterparty risk for both parties.
What an account unlocks
Every completed transaction in Gradientech, with date and price per share.
The order book's price picture, updated in real time.
Largest owners, annual reports and issue terms.
A notice when new interest is registered or the price moves.
Gradientech is a Swedish in vitro diagnostics company specializing in ultra-fast antibiotic susceptibility testing (AST). Their flagship product, QuickMIC®, is designed to empower modern microbiology laboratories by delivering accurate minimum inhibitory concentration (MIC) values directly from positive blood cultures within 2-4 hours. The technology enables faster and more informed treatment decisions, improving healthcare and reducing the spread of antibiotic resistance.
Note: Information on Gradientech is sourced from official channels and public sources unless otherwise stated.
Major Shareholders in Gradientech
| Owner | Share |
|---|---|
| Monesi Förvaltnings AB | 15.98 % |
| INTESA SAN PAOLO SPA, W8IMY | 4.31 % |
| Mikael Lönn | 1.59 % |
| Almi Invest AB | 1.50 % |
| Jarl Ingvar Andersson | 1.47 % |
Source: Eivora (6/30/2026) · Information on Gradientech's ownership structure is sourced from public company registers and external data providers unless otherwise stated.
Gradientech key figures
| Key figures (SEK) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Income statement | |||
| Net sales | 4,457,000 | 1,950,000 | 988,000 |
| Operating result (EBIT) | -64,007,000 | -63,493,000 | -61,008,000 |
| EBITDA | -62,138 | -61,666 | -59,712 |
| Net profit for the year | -63,620,000 | -63,678,000 | -60,962,000 |
| Balance sheet | |||
| Total assets | 40,964,000 | 56,202,000 | 54,752,000 |
| Cash and bank | 24,595,000 | 10,811,000 | 21,177,000 |
| Current liabilities | 5,540,000 | 7,751,000 | 8,175,000 |
| Ratios | |||
| EBITDA margin | -4,080.0 % | -1,411.8 % | -1,252.9 % |
| Equity ratio | 86.5 % | 86.2 % | 85.1 % |
| Employees | 33 | 34 | 23 |
Figures come from the company's filed annual reports. Consolidated accounts are shown where they exist, otherwise the parent company.
Interested in Gradientech shares?
Create an account to see completed trades and order depth, or call us if you would rather talk through the price picture first.
News about Gradientech
Uppsalabolag tar in 55 miljoner
Det Uppsalabaserade företaget genomförde nyligen ett vd-byte och den nya vd:n Sumi Thaker ska ta bolaget in i en fas med fokus på internationell marknadsexpansion för den egenutvecklade diagnostikplattformen Quickmic.
Klart med Gradientechs nya vd
Sumi Thaker har utsetts till ny verkställande direktör för Gradientech. Han har lång erfarenhet från ledande befattningar inom läkemedels- och diagnostikindustrin.
Gradientech appoints Sumi Thaker as Chief Executive Officer to lead its next phase of commercial growth
Gradientech, a diagnostics company pioneering ultra-rapid antibiotic susceptibility testing, today announces the appointment of Sumi Thaker as Chief Executive Officer, with effective date 1 August 2026. Sumi will lead the company’s next phase of growth as Gradientech accelerates the global commercialisation of QuickMIC®.
FAQ
Gradientech is an unlisted company, meaning the shares are not traded on any exchange. Instead, transactions take place through direct transfers between parties, known as secondary trading, typically via a specialised platform for unlisted shares such as Accumeo. For larger international companies, investing through fund structures that pool several investors into a single ownership vehicle is also common. This allows smaller minimum investments and opens up access to international companies for non-institutional investors.
Yes, it is possible to buy existing shares in Gradientech through secondary trading. On Accumeo you create a free account, submit an expression of interest with an amount and any conditions, and may then be matched with a seller. Once both parties have signed the customer agreement, a share transfer agreement is drawn up covering price, share count, and settlement date.
Yes, secondary trading is often the only realistic route to liquidity for an unlisted holding before an IPO or acquisition. Via Accumeo you submit an expression of interest with a share count and target price, and a match may be made with a potential buyer. The sale is executed through a share transfer agreement and registered either via Euroclear or directly in the company's share register, depending on how ownership is administered.
Unlisted companies have no continuous share price because there is no continuous exchange trading. The value is instead based on the latest secondary-market trade or on the price per share from the most recent share issuance. Accumeo shows both historical transaction prices and current bid/ask quotes, providing a combined reference point for pricing.
The value of an unlisted share is most often based on the latest trade — the price buyer and seller agreed in a transaction — or on the latest funding round, where the company and its investors agreed a price for the newly issued shares. These are the reference points shown on Accumeo's platform. It is, however, important to form your own view of value by examining the company's prospects. Financial reports, growth opportunities, market position, and comparable transactions in the sector all help to build a better picture of how the business may develop. Useful information can be found on the company's own website, via Accumeo's platform, and on services like allabolag.se.
No, Gradientech is an unlisted company and its shares are not traded on the Stockholm Stock Exchange, NYSE, or any other regulated marketplace. Shares are instead traded through secondary trading between investors, typically via a specialised platform such as Accumeo.
Yes. Shares in Gradientech can be delivered to an ordinary securities account with a broker such as Avanza or Nordnet, and are registered as the transaction completes.
We hold no registered transfer restrictions for Gradientech. The articles of association are what decide this, so read them before placing an order — restrictions can be added without showing up in public sources.
Disclaimer: The information in this FAQ is provided for informational purposes only and does not constitute an offer to buy or sell securities, a solicitation of such an offer, or investment advice. Accumeo has no commercial relationship with the companies whose securities are mentioned. Independent advice should be obtained before making any investment decision.
Start exploring unlisted shares today
Join 5,000+ investors already trading unlisted shares. Create an account in 2 minutes with BankID — completely free.